covaxin: Covaxin well tolerated, phase 3 data shows 77.8% efficacy against symptomatic Covid: Lancet
thenewsapi
2021-11-12 00:15
covaxin: Covaxin well tolerated, phase 3 data shows 77.8% efficacy against symptomatic Covid: Lancet
India News: A week after the World Health Organisation (WHO) granted Emergency Use Listing (EUL) to Covaxin, a prestigious medical journal Lancet has stated tha...

https://timesofindia.indiatimes.com/india/covaxin-well-tolerated-phase-3-data-shows-77-8-efficacy-against-symptomatic-covid-lancet/articleshow/87655618.cms

#timesofindia #India
Göm kommentarerna Kommentarer (0)

Du måste logga in före du kommenterar